MedTrace Logo

A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

NCT02626754 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2018-06-26

No results posted yet for this study

Summary

This is a multi-national, phase II, single arm study to explore the safety/efficacy and potential biomarkers on sunitinib 2/1 schedule for Asian patients with advanced renal cell carcinoma.

Conditions

Interventions

DRUG

Sunitinib malate

Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.

Sponsors & Collaborators

  • vghtpe user

    lead OTHER_GOV

Principal Investigators

  • Yen-Hwa Chang, M.D. Ph.D. · Taipei Veterans General Hospital, Taiwan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-12
Primary Completion
2018-01-02
Completion
2018-01-02

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02626754 on ClinicalTrials.gov